Back to Awarded Treatment Trials
Awarded Trial: 00-162
Grant ID
00-162
Illness
Schizophrenia
Primary Drug/Intervention
DMXB-A
Primary Dosage
75 or 150 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Freedman
Sample Size
40
Duration of Study Period for Each Subject
one day
Outcome Measurements
RBANS, P50 auditory evoked potential inhibition
Results
Significant neurocognitive improvement was found on the Repeatable Battery for the Assessment of Neuropsychological Status total scale score, particularly for the lower DMXB-A dose compared with placebo. Effects were greater than those of nicotine in a similar study. Significant improvement in P50 inhibition also occurred. Patients generally tolerated the drug well.
Publication
Olincy, A. et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006 Jun;63(6):630-8.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16754836
PI Name
Robert Freedman
Degree
MD
Center
Department of Psychiatry
Institution
University of Colorado Health Sciences Center
Address
Box C-268-71, 4200 E. Ninth Avenue
City or Town
Denver
State or Province
CO
Zip or Postal Code
80262
Country
USA
Email Address
Robert.Freedman@UCHSC.edu